DRTS Stock Forecast & Price Target

Alpha Tau Medical has achieved a significant operational milestone by securing a radioactive material license from the New Hampshire Bureau of Public Health Protection, facilitating the U.S. manufacturing of its proprietary Alpha DaRT technology, set to commence in 2026. The company maintains a strong cash position, which supports its ongoing development in the oncology therapeutics space, particularly in addressing unmet needs associated with solid tumors. Although the company reported a net loss of $11.7 million for the recent period, this figure was only moderately higher than previously estimated, indicating a stable financial trajectory as they progress in their clinical endeavors.

Alpha Tau Medical reported a net loss of $11.7 million for the third quarter of 2025, highlighting ongoing financial challenges as it navigates a critical phase in its development. The company faces significant risks, including the potential failure of its Alpha DaRT technology in clinical trials and difficulties in securing regulatory approval in the U.S., which could hinder its commercial viability. Additionally, concerns regarding market size, competition, and possible dilution further contribute to a negative outlook on the company's stock.